Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 9Ovarian Neoplasms 1Neoplasm Metastasis 1Fallopian Tube Neoplasms 1Estrogen Receptor Positive 1Endometrial Neoplasms 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1Brain Neoplasms 1Anatomic Stage IV Breast Cancer AJCC v8 1

Interventions

Tamoxifen 5Specimen Handling 4Radiotherapy 3Chemotherapy, Adjuvant 2Biopsy 2pembrolizumab 1exemestane 1Watchful Waiting 1Therapeutics 1Sulindac 1Radiation 1Psychiatric Rehabilitation 1Omacor 1Observation 1Norethindrone Acetate 1Neoadjuvant Therapy 1Molecular Diagnostic Techniques 1Magnetic Resonance Spectroscopy 1Letrozole 1Hypnosis 1High-Energy Shock Waves 1Gene Expression Profiling 1Fulvestrant 1Estradiol 1Early Intervention, Educational 1Docosahexaenoic Acids 1Bexarotene 1Atorvastatin 1Anastrozole 1Analgesia 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Breast Carcinoma In Situ × Fulvestrant × Clear all
NCT00126464 2013-11-06

Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the Breast

National Cancer Institute (NCI)

Phase NA Unknown
100 enrolled
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡